COVID-19 medicines

Originally authorised COVID-19 vaccines

The table below lists the COVID-19 vaccines that were originally authorised and that can still be used in the EU. 

The companies marketing these vaccines can submit an application to change their current marketing authorisation to include an adapted version.

Read more in the Adapted COVID-19 vaccines section.

VaccineMarketing authorisation holderKey milestonesMore information
COVID-19 Vaccine (inactivated, adjuvanted) ValnevaValneva Austria GmbHMarketing authorisation issued: 24/06/2022

Latest news

Product information

Paediatric investigation plan

NuvaxovidNovavax CZ, a.s.

Conditional marketing authorisation issued: 20/12/2021

Annual renewal issued: 03/10/2022

Latest news

Product information

Clinical data (login required)

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)AstraZeneca AB

Conditional marketing authorisation issued: 29/01/2021

Annual renewal issued: 09/11/2021

Standard marketing authorisation issued: 31/10/2022


Clinical data (login required)

Spikevax (previously COVID-19 Vaccine Moderna)

Moderna Biotech Spain S.L.

Conditional marketing authorisation issued: 06/01/2021

Annual renewal issued: 04/10/2021

Standard marketing authorisation issued: 03/10/2022 


Clinical data (login required)

Comirnaty(developed by BioNTech and Pfizer)

BioNTech Manufacturing GmbH

Conditional marketing authorisation issued: 21/12/2020

Annual renewal issued: 03/11/2021

Standard marketing authorisation issued: 10/10/2022

Clinical data (login required)

Jcovden (previously COVID-19 Vaccine Janssen)

Janssen-Cilag International NV

Conditional marketing authorisation issued: 11/03/2021

Annual renewal issued: 03/01/2022

Standard marketing authorisation issued: 10/01/2023


Clinical data (login required)
VidPrevtyn BetaSanofi PasteurMarketing authorisation issued: 10/11/2022

Latest news

Product information

Bimervax (previously COVID-19 Vaccine HIPRA) HIPRA Human Health S.L.U.Marketing authorisation issued: 30/03/2023

Latest news

Product information

For more information on how EMA evaluated these vaccines, see:

Adapted COVID-19 vaccines

The table below lists the adapted versions of authorised COVID-19 vaccines.

Adapted vaccines are intended to provide broader protection against different virus variants following initial vaccination. 

Companies need to submit an application to change the marketing authorisation of the originally authorised vaccine.

The table lists adapted vaccines that are already authorised or under evaluation.

VaccineMarketing authorisation holderKey milestonesMore information
Spikevax (previously COVID-19 Vaccine Moderna)Moderna Biotech Spain S.L.

Spikevax bivalent Original/Omicron BA.1

Authorisation issued: 01/09/2022

Spikevax bivalent Original/Omicron BA.4-5

Authorisation issued: 20/10/2022

Comirnaty(developed by BioNTech and Pfizer)

BioNTech Manufacturing GmbH

Comirnaty Original/Omicron BA.1

Authorisation issued: 01/09/2022

Comirnaty Original/Omicron BA.4-5

Authorisation issued: 12/09/2022

For more information, see: 

Authorised COVID-19 treatments

COVID-19 vaccines: strains, use and age ranges

The overview below summarises the characteristics of the COVID-19 vaccines authorised in the EU:

  • Platforms - the type of technology used to develop the vaccine
  • Strains - the type of virus the vaccine targets, i.e. 'wild-type' (original), a variant or a sub-variant of the virus
  • Use - whether the vaccine is for primary or for booster vaccination
  • Population - which age groups the vaccine is used in

This overview also details the composition of COVID-19 vaccines (Figure 1) and the milestones for authorisation of adapted vaccines (Figure 2).

Click on the images below for high resolution versions

Overview of authorised COVID-19 vaccines 

Information on authorised COVID-19 vaccines, including their usage, age ranges and virus strains.

* Figure 1: Available platforms 

Information on the platforms used to develop COVID-19 vaccines.

** Figure 2: Milestones for adapted COVID-19 vaccines

Milestones for the authorisation of COVID-19 vaccines, including adapted vaccines.

Safety information for authorised COVID-19 vaccines

EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any rare side effects that may emerge once many millions of people are vaccinated.

Safety information on each COVID-19 vaccine is available:

Ongoing clinical trials

Information on ongoing clinical trials for COVID-19 treatments in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):

Users can find information on:

  • phase II to phase IV adult clinical trials for COVID-19 treatments where the investigator sites are in the EEA;
  • any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.

Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.

For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see:

How useful was this page?

Add your rating